{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:01:41Z","timestamp":1790186501196,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Southern Denmark","id":[{"id":"https:\/\/ror.org\/03yrrjy16","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The proportion of suspected adverse drug reactions (ADRs) that are formally reported to official pharmacovigilance databases is unclear, although this is essential for patient safety. This systematic literature review aimed to compare the level of formal reporting of ADRs to pharmacovigilance databases with the level of informal reporting of ADRs identified in clinical settings. Further, it aimed to investigate factors that could influence formal ADR reporting. A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement. A review protocol was registered a priori. Embase and Medline were searched for studies published between 1st January 2015 and 17th June 2025 that were based on original data and provided quantitative comparisons between formal and informal ADR reports for any medication type. Reviews, meta-analyses, randomized controlled trials, case reports, case studies, letters to editors, and nonhuman studies were excluded. Four independent reviewers screened the studies and extracted the data pairwise. For each study, we calculated the proportion of identified suspected ADRs that were not formally reported to pharmacovigilance databases and presented them using median and interquartile range (IQR). Risk of bias was assessed using the Critical Appraisal Skills Programme (CASP) checklist. The certainty of evidence was rated using the Grading of Recommendations Assessment, Development and Evaluation\n                    <jats:bold>(<\/jats:bold>\n                    GRADE) approach. Of the 12,558 studies identified, 11 cross-sectional studies were included in the review. These studies included a total of 38,962 patients across all age groups (range 0\u201396\u00a0years) and investigated different medications. The nonreporting estimates ranged between 71.7 and 100%, with a median rate of 98.05% (IQR 95.5\u201399.3). Formal ADR reporting was low regardless of severity or seriousness, suggesting that these factors did not meaningfully influence reporting rates. The studies were heterogeneous and had considerable risk of bias according to CASP. The overall certainty of evidence was rated as very low. A large proportion of ADRs suspected in clinical settings are not formally reported to pharmacovigilance databases. This could constitute a patient safety risk, and future studies should identify key factors that influence formal ADR reporting in order to guide improvements.\n                  <\/jats:p>","DOI":"10.1007\/s00210-026-05917-2","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:35:29Z","timestamp":1790138129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reporting of suspected adverse drug reactions: a systematic review comparing clinical settings and pharmacovigilance systems"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7526-6279","authenticated-orcid":false,"given":"Anemone Kolbak","family":"Nohr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2436-367X","authenticated-orcid":false,"given":"Henriette","family":"Edemann-Callesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0897-3963","authenticated-orcid":false,"given":"Anne Marie Lundskov","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5417-5736","authenticated-orcid":false,"given":"Sarah Grube","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5479-266X","authenticated-orcid":false,"given":"Frederikke","family":"Bondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9700-2739","authenticated-orcid":false,"given":"Rikke","family":"Wesselhoeft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"5917_CR1","doi-asserted-by":"publisher","first-page":"204209862093859","DOI":"10.1177\/2042098620938595","volume":"11","author":"M Alomar","year":"2020","unstructured":"Alomar M, Tawfiq AM, Hassan N, Palaian S (2020) Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Ther Adv Drug Saf 11:2042098620938595. https:\/\/doi.org\/10.1177\/2042098620938595","journal-title":"Ther Adv Drug Saf"},{"issue":"4","key":"5917_CR2","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/bcp.13159","volume":"83","author":"R Al Dweik","year":"2017","unstructured":"Al Dweik R, Stacey D, Kohen D, Yaya S (2017) Factors affecting patient reporting of adverse drug reactions: a systematic review. Br J Clin Pharmacol 83(4):875\u2013883. https:\/\/doi.org\/10.1111\/bcp.13159","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"5917_CR3","first-page":"404","volume":"7","author":"K Bai Sravanthai","year":"2023","unstructured":"Bai Sravanthai K, Venu V (2023) Role of pharmacovigilance in drug discovery & post-marketing surveillance. Int J Trend Sci Res Dev 7(3):404\u2013410","journal-title":"Int J Trend Sci Res Dev"},{"issue":"9","key":"5917_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0291482","volume":"18","author":"RO Buabeng","year":"2023","unstructured":"Buabeng RO, Dsane-Aidoo P, Asamoah YK, Bandoh DA, Boahen YA, Sabblah GT et al (2023) Under-reporting of adverse drug reactions: surveillance system evaluation in Ho Municipality of the Volta Region, Ghana. PLoS ONE 18(9):e0291482. https:\/\/doi.org\/10.1371\/journal.pone.0291482","journal-title":"PLoS ONE"},{"key":"5917_CR5","unstructured":"CASP (2024) Critical Appraisal Checklists https:\/\/casp-uk.net\/casp-tools-checklists\/. Accessed 2 Dec 2025"},{"key":"5917_CR6","unstructured":"Covidence (2025) Covidence \u2013 better systematic review management"},{"issue":"6","key":"5917_CR7","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s11096-023-01592-y","volume":"45","author":"C Costa","year":"2023","unstructured":"Costa C, Abeijon P, Rodrigues DA, Figueiras A, Herdeiro MT, Torre C (2023) Factors associated with underreporting of adverse drug reactions by patients: a systematic review. Int J Clin Pharm 45(6):1349\u20131358. https:\/\/doi.org\/10.1007\/s11096-023-01592-y","journal-title":"Int J Clin Pharm"},{"key":"5917_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/dhps.S205119","volume":"11","author":"JEL Cornwall","year":"2019","unstructured":"Cornwall JEL, Bygum A, Rasmussen ER (2019) ACE-inhibitor related angioedema is not sufficiently reported to the Danish Adverse Drug Reactions Database. Drug Healthc Patient Saf 11:105\u2013113. https:\/\/doi.org\/10.2147\/dhps.S205119","journal-title":"Drug Healthc Patient Saf"},{"key":"5917_CR9","unstructured":"Danish Medicines Agency Registration and monitoring. https:\/\/laegemiddelstyrelsen.dk\/en\/sideeffects\/side-effects-of-medicines\/registration-and-monitoring\/?utm_source=chatgpt.com (2026). Accessed."},{"key":"5917_CR10","unstructured":"Danish Medicines Agency (DKMA) (2024) Side effects of medicines. https:\/\/laegemiddelstyrelsen.dk\/en\/sideeffects\/side-effects-of-medicines\/. Accessed 20 Nov 2025"},{"key":"5917_CR11","unstructured":"Danish Medicines Agency (DKMA) (2025) Report side effects of medicines for human use. https:\/\/laegemiddelstyrelsen.dk\/en\/sideeffects\/side-effects-of-medicines\/report-a-side-effect\/%7E\/link.aspx?_id=6B84AE2577A04EB29B0A47F444BD6548&_z=z. Accessed 20 Nov 2025"},{"issue":"4","key":"5917_CR12","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40272-020-00405-3","volume":"22","author":"ATM Dittrich","year":"2020","unstructured":"Dittrich ATM, Draaisma JMT, van Puijenbroek EP, Loo DMWMT (2020) Analysis of reporting adverse drug reactions in paediatric patients in a university hospital in the Netherlands. Paediatr Drugs 22(4):425\u2013432. https:\/\/doi.org\/10.1007\/s40272-020-00405-3","journal-title":"Paediatr Drugs"},{"key":"5917_CR13","unstructured":"European Medicines Agency (EMA) (1995) ICH Topic E 2 A clinical safety data management: definitions and standards for expedited reporting. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-topic-e-2-clinical-safety-data-management-definitions-and-standards-expedited-reporting-step_en.pdf. Accessed 2 Dec 2025"},{"key":"5917_CR14","unstructured":"European Medicines Agency (EMA) EudraVigilance electronic reporting. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/pharmacovigilance-research-development\/eudravigilance\/eudravigilance-electronic-reporting Accessed 2 Dec 2025"},{"issue":"1","key":"5917_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/ajhp\/zxz261","volume":"77","author":"PM Fina","year":"2020","unstructured":"Fina PM, Cunningham FE, Zhao X, Glassman PA, Moore VR, Au A et al (2020) Reporting of adverse drug events in the Veterans Health Administration for patients whose treatment with empagliflozin or apixaban was discontinued. Am J Health Syst Pharm 77(1):22\u201332. https:\/\/doi.org\/10.1093\/ajhp\/zxz261","journal-title":"Am J Health Syst Pharm"},{"issue":"7","key":"5917_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40264-023-01302-7","volume":"46","author":"P Garc\u00eda-Abeijon","year":"2023","unstructured":"Garc\u00eda-Abeijon P, Costa C, Taracido M, Herdeiro MT, Torre C, Figueiras A (2023) Factors associated with underreporting of adverse drug reactions by health care professionals: a systematic review update. Drug Saf 46(7):625\u2013636. https:\/\/doi.org\/10.1007\/s40264-023-01302-7","journal-title":"Drug Saf"},{"issue":"12","key":"5917_CR17","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.cjco.2024.09.003","volume":"6","author":"LB Guefack Djiokeng","year":"2024","unstructured":"Guefack Djiokeng LB, Todkar S, Corbin S, Lavall\u00e9e M, Pradhan P, Thibault M et al (2024) Impact of Vanessa\u2019s law on the reporting of serious adverse events: a retrospective study among antiplatelet users in a tertiary-care cardiology centre. CJC Open 6(12):1527\u20131533. https:\/\/doi.org\/10.1016\/j.cjco.2024.09.003","journal-title":"CJC Open"},{"issue":"5","key":"5917_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA (2006) Under-reporting of adverse drug reactions\u202f: a systematic review. Drug Saf 29(5):385\u2013396. https:\/\/doi.org\/10.2165\/00002018-200629050-00003","journal-title":"Drug Saf"},{"issue":"9","key":"5917_CR19","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.cgh.2015.02.024","volume":"13","author":"PH Hayashi","year":"2015","unstructured":"Hayashi PH, Fontana RJ, Chalasani NP, Stolz AA, Talwalkar JA, Navarro VJ et al (2015) Under-reporting and poor adherence to monitoring guidelines for severe cases of isoniazid hepatotoxicity. Clin Gastroenterol Hepatol 13(9):1676\u201382.e1. https:\/\/doi.org\/10.1016\/j.cgh.2015.02.024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5917_CR20","unstructured":"Ignacio Neumann SB, Joerg M, Marina D, Pablo AC, Elie A, Philipp D, Nicole S, Jun X, Jan B, Holger J (2026) Sch\u00fcnemann: GRADE Book. https:\/\/book.gradepro.org\/guideline\/overview-of-the-grade-approach Accessed 24 Feb 2026"},{"key":"5917_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzae109","author":"M Lavall\u00e9e","year":"2024","unstructured":"Lavall\u00e9e M, Corbin S, Pradhan P, Guefack LB, Thibault M, Methot J et al (2024) Underreporting of adverse events to health authorities by healthcare professionals: a red flag-raising descriptive study. Int J Qual Health Care. https:\/\/doi.org\/10.1093\/intqhc\/mzae109","journal-title":"Int J Qual Health Care"},{"issue":"10","key":"5917_CR22","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1080\/14740338.2021.1938539","volume":"20","author":"R Li","year":"2021","unstructured":"Li R, Curtis K, Zaidi STR, Van C, Thomson A, Castelino R (2021) Prevalence, characteristics, and reporting of adverse drug reactions in an Australian hospital: a retrospective review of hospital admissions due to adverse drug reactions. Expert Opin Drug Saf 20(10):1267\u20131274. https:\/\/doi.org\/10.1080\/14740338.2021.1938539","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"5917_CR23","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1080\/14740338.2022.2118712","volume":"21","author":"R Li","year":"2022","unstructured":"Li R, Curtis K, Zaidi ST, Van C, Castelino R (2022) A new paradigm in adverse drug reaction reporting: consolidating the evidence for an intervention to improve reporting. Expert Opin Drug Saf 21(9):1193\u20131204. https:\/\/doi.org\/10.1080\/14740338.2022.2118712","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"5917_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pds.4906","volume":"29","author":"R Li","year":"2020","unstructured":"Li R, Zaidi STR, Chen T, Castelino R (2020) Effectiveness of interventions to improve adverse drug reaction reporting by healthcare professionals over the last decade: a systematic review. Pharmacoepidemiol Drug Saf 29(1):1\u20138. https:\/\/doi.org\/10.1002\/pds.4906","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"5917_CR25","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/pds.3663","volume":"24","author":"F Meier","year":"2015","unstructured":"Meier F, Maas R, Sonst A, Patapovas A, M\u00fcller F, Plank-Kiegele B et al (2015) Adverse drug events in patients admitted to an emergency department: an analysis of direct costs. Pharmacoepidemiol Drug Saf 24(2):176\u2013186. https:\/\/doi.org\/10.1002\/pds.3663","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5917_CR26","unstructured":"Medicines and Healthcare Products Regulatory Agency (MHRA) (2015) the Yellow Card scheme: guidance for healthcare professionals, patients and the public. https:\/\/www.gov.uk\/guidance\/the-yellow-card-scheme-guidance-for-healthcare-professionals?utm_source=chatgpt.com. Accessed"},{"issue":"3","key":"5917_CR27","doi-asserted-by":"publisher","first-page":"276","DOI":"10.11613\/BM.2012.031","volume":"22","author":"ML McHugh","year":"2012","unstructured":"McHugh ML (2012) Interrater reliability: the kappa statistic. Biochem Med (Zagreb) 22(3):276\u2013282","journal-title":"Biochem Med (Zagreb)"},{"issue":"1","key":"5917_CR28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00228-022-03419-7","volume":"79","author":"TK Patel","year":"2023","unstructured":"Patel TK, Patel PB, Bhalla HL, Dwivedi P, Bajpai V, Kishore S (2023) Impact of suspected adverse drug reactions on mortality and length of hospital stay in the hospitalised patients: a meta-analysis. Eur J Clin Pharmacol 79(1):99\u2013116. https:\/\/doi.org\/10.1007\/s00228-022-03419-7","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"5917_CR29","doi-asserted-by":"publisher","first-page":"e0162948","DOI":"10.1371\/journal.pone.0162948","volume":"11","author":"DM Rydberg","year":"2016","unstructured":"Rydberg DM, Holm L, Engqvist I, Fryckstedt J, Lindh JD, Stiller CO et al (2016) Adverse drug reactions in a tertiary care emergency medicine ward - prevalence, preventability and reporting. PLoS ONE 11(9):e0162948. https:\/\/doi.org\/10.1371\/journal.pone.0162948","journal-title":"PLoS ONE"},{"issue":"4","key":"5917_CR30","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s11096-023-01601-0","volume":"45","author":"P Shuttleworth","year":"2023","unstructured":"Shuttleworth P, Baker J, Clark E (2023) Under-reporting of gastrointestinal bleeding associated with anticoagulant use using the UK yellow card scheme. Int J Clin Pharm 45(4):1014\u20131018. https:\/\/doi.org\/10.1007\/s11096-023-01601-0","journal-title":"Int J Clin Pharm"},{"key":"5917_CR31","unstructured":"World Health Organization (WHO) (2025) Briefing Note. Safety of medicines -adverse drug reactions. https:\/\/www.who.int\/docs\/default-source\/medicines\/safety-of-medicines--adverse-drug-reactions-jun18.pdf?sfvrsn=4fcaf40_2 Accessed 2 Dec 2025"},{"issue":"4","key":"5917_CR32","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1177\/10600280211032404","volume":"56","author":"WJ Whitehead","year":"2022","unstructured":"Whitehead WJ, Reid JM (2022) Underreported risk of lisinopril-induced angioedema in a veteran population. Ann Pharmacother 56(4):430\u2013435. https:\/\/doi.org\/10.1177\/10600280211032404","journal-title":"Ann Pharmacother"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05917-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05917-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05917-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:03:20Z","timestamp":1790183000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05917-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":32,"alternative-id":["5917"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05917-2","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"2 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was not required due to the study design.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable\n                      .","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was registered at PROSPERO (CRD420251086773).","order":5,"name":"Ethics","label":"Protocol","group":{"name":"EthicsHeading","label":"Declarations"}}]}}